scholarly journals Role of tacrolimus combination therapy with mycophenolate mofetil in the prevention of organ rejection in kidney transplant patients

2010 ◽  
pp. 107 ◽  
Author(s):  
Lorenzo Gallon ◽  
Pranav Dalal ◽  
Shah ◽  
Chhara
Keyword(s):  
Mycophenolate Mofetil ◽  
Combination Therapy ◽  
Kidney Transplant ◽  
Organ Rejection ◽  
Transplant Patients ◽  
Kidney Transplant Patients

scholarly journals Immune Response after SARS-CoV-2 Vaccination in Kidney Transplant Patients

Medicina ◽  
2021 ◽  
Vol 57 (12) ◽  
pp. 1327
Author(s):  
Ruta Vaiciuniene ◽  
Brigita Sitkauskiene ◽  
Inga Arune Bumblyte ◽  
Egle Dalinkeviciene ◽  
Edita Ziginskiene ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Antibody Response ◽  
Kidney Transplant ◽  
Kidney Function ◽  
Hemoglobin Level ◽  
Total Leucocyte Count ◽  
Binary Logistic Regression Analysis ◽  
Cd8 Cells ◽  
Transplant Patients ◽  
Kidney Transplant Patients

Background and Objectives: The prospective study was conducted to evaluate humoral and cellular immune responses after two doses of BNT162b2 (Pfizer-BioNTech) vaccine and possible relation with other factors (medication, etc.) in kidney transplant patients. Materials and Methods: Out of 167 vaccinated patients, 136 agreed to a follow-up visit three to six weeks after vaccination. Results: Only 39 patients (29%) developed antibody response against SARS-CoV-2 (≥35.2 binding antibody units (BAU)/mL) after full vaccination. Multivariate binary logistic regression analysis showed that predictive factors for good antibody response to the COVID-19 vaccine were better kidney function, higher hemoglobin level, and no use of mycophenolate mofetil for immunosuppression. For seropositive kidney transplant patients there was a significant negative correlation between anti-SARS-CoV-2 antibody titer and CD4/CD8 ratio (Spearman’s correlation coefficient −0.4, p = 0.02), percentage of CD19+ cells (r = −0.37, p = 0.02), and a positive correlation with percentage of CD8+ cells (r = 0.4, p = 0.01). There was an increase of total leucocyte count after vaccination in the total studied population, and in the group of responders. Conclusions: Only one third of kidney transplant patients develop sufficient antibody responses after full COVID-19 vaccination with Pfizer-BioNTech. Better kidney function, higher hemoglobin level, and no use of mycophenolate mofetil for immunosuppression increases the adequacy of response. The antibody titers correlated positively with relative number of CD8+ cells and negatively with CD4/CD8 ratio in responders.

Variability of Mycophenolate Mofetil Trough Levels in Stable Kidney Transplant Patients

2007 ◽  
Vol 39 (7) ◽  
pp. 2185-2186 ◽  
Author(s):  
A. Fernández ◽  
J. Martins ◽  
J.J. Villlafruela ◽  
R. Marcén ◽  
J. Pascual ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Kidney Transplant ◽  
Transplant Patients ◽  
Kidney Transplant Patients ◽  
Trough Levels

Coadministration of Tacrolimus and Mycophenolate Mofetil in Stable Kidney Transplant Patients: Pharmacokinetics and Tolerability

2000 ◽  
Vol 40 (5) ◽  
pp. 527-532 ◽  
Author(s):  
John Pirsch ◽  
Ihor Bekersky ◽  
Flavio Vincenti ◽  
Garry Boswell ◽  
E. Steve Woodle ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Kidney Transplant ◽  
Transplant Patients ◽  
Kidney Transplant Patients

scholarly journals The role of soluble mediators in the clinical course of EBV infection and B cell homeostasis after kidney transplantation

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Sharon Bajda ◽  
Arturo Blazquez-Navarro ◽  
Björn Samans ◽  
Patrizia Wehler ◽  
Sviatlana Kaliszczyk ◽  
...  
Keyword(s):  
B Cell ◽  
Kidney Transplant ◽  
Cell Expansion ◽  
Soluble Factors ◽  
Post Transplant ◽  
Transplant Patients ◽  
Proliferative Effect ◽  
Kidney Transplant Patients ◽  
B Cell Homeostasis

Abstract Epstein-Barr virus (EBV) reactivation can lead to serious complications in kidney transplant patients, including post-transplant lymphoproliferative disorder (PTLD). Here, we have assessed the impact of EBV on B cell homeostasis at cellular and humoral level. In a multicenter study monitoring 540 kidney transplant patients during the first post-transplant year, EBV reactivation was detected in 109 patients. Thirteen soluble factors and B cell counts were analyzed in an EBV+ sub-cohort (N = 54) before, at peak and after EBV clearance and compared to a control group (N = 50). The B cell activating factor (BAFF) was significantly elevated among EBV+ patients. No additional soluble factors were associated with EBV. Importantly, in vitro experiments confirmed the proliferative effect of BAFF on EBV-infected B cells, simultaneously promoting EBV production. In contrast, elevated levels of BAFF in EBV+ patients did not lead to B cell expansion in vivo. Moreover, diminished positive inter-correlations of soluble factors and alterations of the bi-directional interplay between B cell and soluble factors were observed in EBV+ patients at peak and after clearance. Our data suggest that such alterations may counteract the proliferative effect of BAFF, preventing B cell expansion. The role of these alterations in lymphoma development should be analyzed in future studies.

Pharmacokinetics of Mycophenolate Mofetil in Kidney Transplant Patients With Renal Insufficiency

2005 ◽  
Vol 37 (9) ◽  
pp. 3749-3751 ◽  
Author(s):  
F.M. González-Roncero ◽  
M.A. Gentil ◽  
M. Brunet ◽  
G. Algarra ◽  
P. Pereira ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Renal Insufficiency ◽  
Kidney Transplant ◽  
Transplant Patients ◽  
Kidney Transplant Patients
Sign in / Sign up

Export Citation Format

Share Document